An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation

Current Opinion in Hematology

Volumn 4, Issue 6, 1997, Pages 395-400

  Horowitz, Mary M ^a   Rowlings, Philip A ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; DATA BASE; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL TRANSPLANTATION; SURVIVAL TIME;

EID: 0030734536     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704060-00006     Document Type: Short Survey

References (23)

1. Rowlings PA: Current use and outcome of blood and marrow transplantation. ABMTR Newsletter 1996, 3:6-12. Summarizes use and outcome of allogeneic and autologous hematopoietic stem cell transplants reported to the IBMTR and the ABMTR for the years 1989 through 1995. Most recent of a series of yearly updates from the IBMTR/ABMTR Statistical Center. Copies available upon request from the Statistical Center.
2. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, et al.: Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identlcal siblings. J Clin Oncol 1997, 15:1767-1777. Compares outcome of 2055 bone marrow transplantations for leukemia using HLA-identical sibling, HLA-mismatched related, and HLA-matched and -mismatched unrelated donors done between 1985 and 1991 and reported to the IBMTR by 87 centers.
3. Petersdorf EW, Longton GM, Anasetti C, Martin PJ, Mickelson EM, Smith AG, Hansen JA: The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR Identical unrelated donor marrow transplantation. Blood 1995, 86:1606-1613.
4. Petersdorf EW, Longton GM, Anasetti C, Mickelson EM, Smith AG, Martin PJ, Hansen JA: Definition of HLA-DQ as a transplantation antigen. Proc Natl Acad Sci U S A 1996, 93:15358-15363. Examines outcome of 449 HLA-A, -B, and -DR serologically matched unrelated donor transplants, comparing those matched (by molecular typing) for HLA-DRB1 and HLA-DQB1 with those mismatched at HLA-DRB1 and/or -DQB1. Documents increased risks of grade III-IV acute graft-versus-host disease with either DRB1 or DQB1 mismatching.
5. Reiffers J, Bernard P, David B, Vezon G, Sarrat A, Marit G, Moulinier J, Broustet A: Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukaemia. Exp Hematol 1986, 14:312-315.
6. Korbling M, Dorken B, Ho AD, Pezzuto A, Hunstein W, Fliedner TM: Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986, 67:529-532.
7. Kessinger A, Armitage JO, Landmark JD, Weisenberger DD: Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986, 14:192-196.
8. Sheridan WP, Begley CG, Juttner CA, Szer J, Bik TO L, Maher D, McGrath KM, Morstyn G, Fox RM: Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high dose chemotherapy. Lancet 1992, 339:640-644.
9. Bensinger WI, Weaver CH, Appelbaum FR, Rowley S, Demirer T, Sanders J, Storb R, Buckner CD: Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995, 85:1655-1658.
10. Körbling M, Przepiorka D, Huh YO, Engel H, van Besien K, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, Andreeff M, Champlin R: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995, 85:1659-1665.
11. Schmitz N, Dreger P, Suttorp M, Rohwedder EB, Haferlach T, Löffler H, Hunter A, Russell NH: Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995, 85:1666-1672.
12. Wagner JE, Kernan NA, Steinbuch M, Broxmeyer HE, Gluckman E: Allogeneic sibling umbilical cord blood transplantation in children with malignant and non-malignant disease. Lancet 1995, 346:214-219.
13. Kurtzburg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, Ciocci G, Carrier C, Stevens CE, Rubinstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166. Describes results of 25 unrelated umbilical cord blood transplants in patients with advanced malignant and nonmalignant diseases done between 1993 and 1995 at Duke University. Twenty-four of 25 were HLA-mismatched. Forty-three percent developed grade II-IV acute graft-versus-host disease; survival at 1 year was 48%.
14. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, Ortega J, Souillet G, Ferreira E, Laporte J-P, et al.: Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997, 337:373-381. Described 143 results of cord blood transplants-78 from related and 65 from unrelated donors. One-year survival was 63% for related cord blood transplants and 29% for unrelated cord blood transplants. Variables associated with survival were recipient age, weight and cytomegalovirus status, cell dose, and donor-recipient HLA-match.
15. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Bensinger WI, Buckner CD, Cheever MA, Deeg HJ, Doney K, et al.: Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986, 104:155-163.
16. Goldman JM, Szydlo R, Horowitz MM, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A, et al., for the Advisory Committee of the IBMTR: Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993, 82:2235-2238.
17. Passweg JR, Socié G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, Champlin RE, Gale RP, Gluckman E, Gordon-Smith EC, et al.: Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood 1997, 90:858-864. Describes patient-, disease-, and transplant-related characteristics of 1305 recipients of HLA-identical sibling transplants for aplastic anemia between 1976 and 1992. Correlates improvements in survival with changes in transplant strategies, especially graft-versus-host disease prophylaxis.
18. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, Gibson J, Jacobsen N, Klein JP, Kolb HJ, Stevens DA, Horowitz MM, Gale RP: Results of bone marrow transplants from genetically identical twins in persons with aplastic anemia. Ann Intern Med 1997, 126:116-122. Analyzes results of 40 identical twin transplants for aplastic anemia done between 1964 and 1992. Compares transplants done with and without pretransplant immune suppression.
19. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, et al.: Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996, 14:572-578.
20. Antman KH, Rowlings PA, Vaughan WP, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, et al.: High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997, 15:1870-1879. Describes outcome and changing patterns of high-dose therapy with autologous hematopoietic stem cell support for breast cancer. Includes data on 5886 women treated in 170 centers in North and South America.
21. Socié G, Sobocinski KA, Veum-Stone J, Horowitz MM: Long-term survival and analysis of late causes of death after allogeneic bone marrow transplantation (BMT) [abstract]. Blood 1996, 88(suppl 1):643a.
22. Duell T, van Lint MT, Ljungman P, Tichelli A, Socié G, Apperley JF, Weiss M, Cohen A, Nekolla E, Kolb HJ: Health and functional status of long-term survivors of bone marrow transplantation: EBMT Working Party on Late Effects and EULEP Study Group on Late Effects, European Group for Blood and Marrow Transplantation. Ann Intern Med 1997, 126:184-192. Reports on 798 transplant recipients surviving at least 5 years after bone marrow transplantation. Subsequent mortality was 8% at 10 years post-transplantation. Most patients had normal or minimally reduced performance scores and had resumed full-time work or school. Major causes of late death were recurrent cancer, secondary cancers, and chronic graft-versus-host-disease.
23. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socié G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, et al.: Solld tumors developing after allogeneic bone marrow transplantation. N Engl J Med 1997, 336:897-904. Compares incidence of solid tumors in 19,229 transplant recipients with incidence expected in age and sex-matched normal population. Identifies risk factors (young age at transplant, high doses of total body irradiation, chronic graft-versus-host disease) for solid tumors.